Search results
Jun 24, 2024 · [On June 3], a global team of researchers funded by a Stand Up To Cancer (SU2C) grant announced clinical trial results that point to a new immunotherapy treatment option for two of the most common types of soft tissue sarcoma in adults, a breakthrough that reduces the risk of relapse by 43% at two years and will likely impact clinical practice ...
Jun 18, 2024 · Since 2010, Mastercard has supported Stand Up To Cancer’s® (SU2C) mission to make every cancer patient a long-term survivor. Alongside Major League Baseball (MLB), Mastercard is launching a new multi-faceted campaign to empower everyone to tell their stories and stand up for someone they love.
Jun 25, 2024 · Researchers funded by Stand Up To Cancer (SU2C) achieved a breakthrough in treating two common types of soft tissue sarcoma, reducing the risk of relapse by 43 percent at two years. This immunotherapy treatment could significantly impact future clinical practices.
Jun 25, 2024 · A global research team, supported by a Stand Up To Cancer® (SU2C) grant, unveiled clinical trial results indicating a groundbreaking immunotherapy treatment for two prevalent adult soft tissue sarcomas.
5 days ago · A glimmer of hope emerged for patients with sarcoma in a recent clinical trial. Researchers funded by Stand Up To Cancer (SU2C) achieved a breakthrough in treating two common types of soft tissue sarcoma, reducing the risk of relapse by read more about This Sarcoma Clinical Trial Reduces Risk of Relapse by 43%
Jun 26, 2024 · These powerful treatments, which work by bolstering the immune system’s ability to detect and kill cancer cells, have saved countless lives since the first immunotherapy was approved for cancer in 2011. 1 Today, more than 1,000 immunotherapy clinical trials are underway, each exploring different cancers and contexts. 2.
Jun 27, 2024 · Our quest against cancer goes beyond the lab through the Van Andel Institute–Stand Up To Cancer© (SU2C) Epigenetics Dream Team, a collaborative team of scientists, physicians and organizations who work together to move promising new treatments into clinical trials.
